These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 33757970)

  • 21. Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
    Rustum YM; Chintala S; Durrani FA; Bhattacharya A
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A HIF1α-GPD1 feedforward loop inhibits the progression of renal clear cell carcinoma via mitochondrial function and lipid metabolism.
    Liu R; Feng Y; Deng Y; Zou Z; Ye J; Cai Z; Zhu X; Liang Y; Lu J; Zhang H; Luo Y; Han Z; Zhuo Y; Xie Q; Hon CT; Liang Y; Wu CL; Zhong W
    J Exp Clin Cancer Res; 2021 Jun; 40(1):188. PubMed ID: 34098990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

  • 24. Genetic and metabolic hallmarks of clear cell renal cell carcinoma.
    Sanchez DJ; Simon MC
    Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):23-31. PubMed ID: 29959988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity.
    Ochocki JD; Khare S; Hess M; Ackerman D; Qiu B; Daisak JI; Worth AJ; Lin N; Lee P; Xie H; Li B; Wubbenhorst B; Maguire TG; Nathanson KL; Alwine JC; Blair IA; Nissim I; Keith B; Simon MC
    Cell Metab; 2018 Jun; 27(6):1263-1280.e6. PubMed ID: 29754953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells.
    You JH; Lee J; Roh JL
    J Exp Clin Cancer Res; 2021 Nov; 40(1):350. PubMed ID: 34749765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 36-kDa Annexin A3 Isoform Negatively Modulates Lipid Storage in Clear Cell Renal Cell Carcinoma Cells.
    Bombelli S; Torsello B; De Marco S; Lucarelli G; Cifola I; Grasselli C; Strada G; Bovo G; Perego RA; Bianchi C
    Am J Pathol; 2020 Nov; 190(11):2317-2326. PubMed ID: 32861643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
    Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
    Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.
    Yamasaki T; Kamba T; Kanno T; Inoue T; Shibasaki N; Arakaki R; Yamada T; Kondo K; Kamoto T; Nishiyama H; Ogawa O; Nakamura E
    Cancer Sci; 2012 Nov; 103(11):2027-37. PubMed ID: 22931246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma.
    Qiu B; Ackerman D; Sanchez DJ; Li B; Ochocki JD; Grazioli A; Bobrovnikova-Marjon E; Diehl JA; Keith B; Simon MC
    Cancer Discov; 2015 Jun; 5(6):652-67. PubMed ID: 25829424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yin Yang 1 facilitates hepatocellular carcinoma cell lipid metabolism and tumor progression by inhibiting PGC-1β-induced fatty acid oxidation.
    Li Y; Kasim V; Yan X; Li L; Meliala ITS; Huang C; Li Z; Lei K; Song G; Zheng X; Wu S
    Theranostics; 2019; 9(25):7599-7615. PubMed ID: 31695789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
    Nicholson HE; Tariq Z; Housden BE; Jennings RB; Stransky LA; Perrimon N; Signoretti S; Kaelin WG
    Sci Signal; 2019 Oct; 12(601):. PubMed ID: 31575731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. More Than an Adipokine: The Complex Roles of Chemerin Signaling in Cancer.
    Goralski KB; Jackson AE; McKeown BT; Sinal CJ
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soyasapogenol B exhibits anti-growth and anti-metastatic activities in clear cell renal cell carcinoma.
    Wang L; Wang J; Zhao H; Jiang G; Feng X; Sui W; Liu H
    Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):551-563. PubMed ID: 30607469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma.
    Yangyun W; Guowei S; Shufen S; Jie Y; Rui Y; Yu R
    Gene; 2022 Jan; 809():145992. PubMed ID: 34648917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer.
    Chung C
    Am J Health Syst Pharm; 2020 Dec; 77(24):2064-2073. PubMed ID: 33016992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin suppresses lipid accumulation in skeletal muscle by promoting fatty acid oxidation.
    Wang C; Liu F; Yuan Y; Wu J; Wang H; Zhang L; Hu P; Li Z; Li Q; Ye J
    Clin Lab; 2014; 60(6):887-96. PubMed ID: 25016691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
    Joshi S; Singh AR; Durden DL
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation.
    Wang X; Cheng Y; Zhu Y; Li H; Ge W; Wu X; Zhao K; Yuan J; Li Z; Jiang S; Han Z; Jiang Q; Wu Q; Liu T; Zhang C; Yu M; Hu Y
    Int J Cancer; 2017 Oct; 141(7):1422-1433. PubMed ID: 28656647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.